Ads
related to: melanoma to lymph node prognosis- Treatment Modifications
See Recommended Dose Modifications
For Managing Adverse Reactions.
- Co-Pay Assistance
See If Your Melanoma Patients Are
Eligible For Co-Pay Assistance.
- Efficacy Data
Explore Clinical Research On The
Efficacy & Safety Of This Treatment
- Dosing Information
View Dosing Recommendations
For An FDA Approved Treatment.
- Patient Financial Support
HCPs: Find Access & Support Info
For Your Melanoma Patients.
- Prep & Admin
Review Preparation & Administration
For A Melanoma Treatment Option.
- Treatment Modifications
careinfo.mayoclinic.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Neither sentinel lymph node biopsy nor other diagnostic tests should be performed to evaluate early, thin melanoma, including melanoma in situ, T1a melanoma or T1b melanoma ≤ 0.5mm. [114] People with these conditions are unlikely to have the cancer spread to their lymph nodes or anywhere else and have a 5-year survival rate of 97%. [ 114 ]
A large study validated the importance of tumor depth (but not Breslow's original description) as one of the three most important prognostic factors in melanoma (the others being T stage and ulceration). [4] Breslow's depth also accurately predicted the risk for lymph node metastasis, with deeper tumors being more likely to involve the nodes. [5]
Treatment is by excisional biopsy, wide local excision and possibly sentinel node biopsy. Localized melanoma, which has not spread beyond the skin, has a very good prognosis with low recurrence rates. Spread of disease to local lymph nodes or distant sites (typically brain, bone, skin and lung) marks a decidedly poor prognosis.
The prognosis of acral lentiginous melanoma is based on multiple factors including gender, age, race, Breslow depth, staging, and sentinel lymph node positivity. [7] Out of these factors, it is believed that sentinel lymph node positivity provides the strongest prediction of cancer recurrence and death.
Five-year survival is greater than 90% for patients with stage I lesions but decreases to 20% when pelvic lymph nodes are involved. Lymph node involvement is the most important predictor of prognosis. [38] Prognosis depends on the stage of cancer, which refers the amount and spread of cancer in the body. [39] The stages are broken into four ...
For example, it has been found that the prognosis of women who have micrometastases to the sentinel lymph node is poorer than that of women who do not have any evidence of tumor in these lymph nodes. [2] The same applies to patients with melanoma and the other solid tumor cancers. [citation needed]
Ad
related to: melanoma to lymph node prognosis